Andrea Ellis Sells 17,167 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 17,167 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $84.00, for a total value of $1,442,028.00. Following the transaction, the director owned 22,579 shares of the company’s stock, valued at approximately $1,896,636. This represents a 43.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Price Performance

Shares of NASDAQ:BBIO opened at $84.09 on Wednesday. The stock’s 50 day moving average price is $70.31 and its 200 day moving average price is $72.18. BridgeBio Pharma, Inc. has a 12 month low of $42.09 and a 12 month high of $93.42. The stock has a market cap of $16.47 billion, a price-to-earnings ratio of -22.48 and a beta of 0.95.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. The business’s revenue was up 66.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.88) EPS. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -2.3 EPS for the current year.

Analysts Set New Price Targets

BBIO has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Canaccord Genuity Group initiated coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 price target on the stock. Truist Financial upped their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Mizuho decreased their price objective on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research note on Tuesday, June 16th. Finally, Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective on the stock. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average price target of $94.63.

Institutional Trading of BridgeBio Pharma

Institutional investors have recently made changes to their positions in the stock. Brooklands Fund Management Ltd purchased a new position in BridgeBio Pharma during the fourth quarter valued at approximately $210,348,000. Price T Rowe Associates Inc. MD increased its stake in BridgeBio Pharma by 144.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after buying an additional 2,261,181 shares during the period. Janus Henderson Group PLC lifted its position in BridgeBio Pharma by 25.8% in the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after buying an additional 2,259,378 shares in the last quarter. Norges Bank purchased a new stake in BridgeBio Pharma in the 4th quarter worth approximately $116,802,000. Finally, Wellington Management Group LLP boosted its stake in shares of BridgeBio Pharma by 130.4% during the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock valued at $179,654,000 after buying an additional 1,329,537 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright lifted its earnings estimates for BridgeBio Pharma across multiple future periods, including FY2027 EPS to $2.19 from $2.12, while reiterating a Buy rating and a $120 price target. HC Wainwright raises BridgeBio Pharma price target to $120
• Positive Sentiment: HC Wainwright also raised its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 earnings estimates, reinforcing the view that BridgeBio’s earnings trajectory is improving. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: RBC Capital reaffirmed its Buy view on BridgeBio Pharma, adding to the overall positive analyst backdrop. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: A recent article noted BridgeBio could be a relative beneficiary after a competing biotech trial miss, which may have helped sentiment around the sector and the stock. Phase 3 failure sends biotech winners and losers in opposite directions
• Negative Sentiment: Director Andrea Ellis sold 17,167 shares, and another filing shows Director Jennifer E. Cook sold 148,589 shares, which can weigh on investor sentiment even though both trades were made under pre-arranged 10b5-1 plans. Insider selling at BridgeBio Pharma

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.